Advanced Enzyme Technologies Limited has informed the Exchange about Investor Presentation
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies reported Q1 FY26 consolidated revenue of ₹1,859 million, up 20% year-on-year and 11% quarter-on-quarter. EBITDA rose 10% YoY to ₹564 million (30% margin) and profit after tax jumped 16% YoY to ₹404 million (22% margin), with a strong 51% sequential PAT growth. The Human Nutrition segment, contributing 66% of revenue, grew 21% YoY, while Animal Nutrition surged 51% YoY. India led geographical growth at 32% YoY, though the Americas declined 4%. For the full FY25, revenue grew modestly 2% to ₹6,369 million with PAT at ₹1,340 million.
Strong sequential rebound in Q1 FY26 with broad-based segment growth and margin stability signals healthy operational momentum. The mixed geographical performance, especially the Americas decline, may warrant monitoring, but the strong India and Animal Nutrition traction should be viewed positively by shareholders.